Summit Therapeutics
SMMT
17 hedge funds and large institutions have $8.45M invested in Summit Therapeutics in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 7 closing their positions.
1.42% less ownership
Funds ownership: 5.63% → 4.21% (-1.4%)
15% less funds holding
Funds holding: 20 → 17 (-3)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
84% less capital invested
Capital invested by funds: $53.3M → $8.45M (-$44.9M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $45K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$363K |
| 2 |
VF
Virtu Financial
New York
|
+$231K |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$192K |
| 4 |
FFW
Fusion Family Wealth
Woodbury,
New York
|
+$128K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$97.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
-$4.36M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.81M |
| 3 |
HCM
Highbridge Capital Management
New York
|
-$1.03M |
| 4 |
Renaissance Technologies
New York
|
-$714K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$639K |
SMMT Hedge Fund Activity: Q2 2018 in Review
17 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q2 2018, worth a combined $8.45M — down 84% from $53.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SMMT and 4 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was Millennium Management, adding an estimated $363K. The largest seller was Axa, exiting entirely with an estimated $4.36M sold.
- 17 institutional investors held Summit Therapeutics (SMMT) as of Q2 2018, down from 20 in Q1 2018.
- Funds reported $8.45M of Summit Therapeutics stock for Q2 2018, down 84% quarter-over-quarter.
- 4 funds opened new Summit Therapeutics positions in Q2 2018 and 7 closed out, a net change of -3 holders.
- The largest Summit Therapeutics buyer in Q2 2018 was Millennium Management, an estimated $363K added.
- The largest Summit Therapeutics seller in Q2 2018 was Axa, an estimated $4.36M sold.
Based on aggregated 13F filings for Q2 2018.